Characterization of pediatric transfusion-dependent thalassemia patients in a large academic center.
alloantibodies
alloimmunization
red blood cell transfusion
thalassemia
transfusion-related complications
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
27
07
2023
received:
09
06
2023
accepted:
23
08
2023
medline:
6
11
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
Transfusion-dependent thalassemia patients are at high risk of transfusion-related complications. Yet, there is scanty data on the frequency of transfusion reactions, particularity alloimmunization among pediatric transfusion-dependent thalassemia patients. In addition, there is no consensus on the prophylactic antigen matching for prevention of alloimmunization or the extent of antigen matching for alloimmunized thalassemia patients. We conducted a retrospective study to assess the frequency and specificity of alloimmunization among pediatric transfusion-dependent thalassemia patients receiving ABO, RhD, and K-matched red blood cell units. In addition, we studied the association between patients' characteristics and alloimmunization. The clinical and transfusion records of transfusion-dependent thalassemia patients followed up at our institution between July 2018 and June 2022 were reviewed. Ninety-two transfusion-dependent thalassemia patients having mean age of 13.37 years (SD, 5.56) were included in our study. Eight patients (9%) had developed clinically significant alloantibodies; six patients (6%) developed alloantibody against E antigen while two patients (2%) developed more than one alloantibody. Of alloimmunized patients, five patients had received transfusion outside Canada. Patients' sex, age, having a genotype variant, total number, and duration of transfusion received were not associated with the risk of alloimmunization. The transfusion-recipient's diagnosis of β-thalassemia, having developed autoantibody, and history of receiving transfusion outside Canada were associated with alloimmunization. Blood matching for ABO, RhD, and K antigens resulted in, although not eliminated, lower frequency of alloimmunization than that previously reported among pediatric thalassemia patients. Extending matching to include Rh antigens could further reduce the rate of alloimmunization.
Sections du résumé
BACKGROUND
BACKGROUND
Transfusion-dependent thalassemia patients are at high risk of transfusion-related complications. Yet, there is scanty data on the frequency of transfusion reactions, particularity alloimmunization among pediatric transfusion-dependent thalassemia patients. In addition, there is no consensus on the prophylactic antigen matching for prevention of alloimmunization or the extent of antigen matching for alloimmunized thalassemia patients.
METHODS
METHODS
We conducted a retrospective study to assess the frequency and specificity of alloimmunization among pediatric transfusion-dependent thalassemia patients receiving ABO, RhD, and K-matched red blood cell units. In addition, we studied the association between patients' characteristics and alloimmunization. The clinical and transfusion records of transfusion-dependent thalassemia patients followed up at our institution between July 2018 and June 2022 were reviewed.
RESULTS
RESULTS
Ninety-two transfusion-dependent thalassemia patients having mean age of 13.37 years (SD, 5.56) were included in our study. Eight patients (9%) had developed clinically significant alloantibodies; six patients (6%) developed alloantibody against E antigen while two patients (2%) developed more than one alloantibody. Of alloimmunized patients, five patients had received transfusion outside Canada. Patients' sex, age, having a genotype variant, total number, and duration of transfusion received were not associated with the risk of alloimmunization. The transfusion-recipient's diagnosis of β-thalassemia, having developed autoantibody, and history of receiving transfusion outside Canada were associated with alloimmunization.
CONCLUSION
CONCLUSIONS
Blood matching for ABO, RhD, and K antigens resulted in, although not eliminated, lower frequency of alloimmunization than that previously reported among pediatric thalassemia patients. Extending matching to include Rh antigens could further reduce the rate of alloimmunization.
Identifiants
pubmed: 37665129
doi: 10.1002/jcla.24962
pmc: PMC10623514
doi:
Substances chimiques
Blood Group Antigens
0
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24962Informations de copyright
© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Blood Transfus. 2019 Jan;17(1):4-15
pubmed: 30653458
Transfusion. 2018 Jun;58(6):1555-1566
pubmed: 29697146
Minerva Pediatr (Torino). 2022 Jun;74(3):365-372
pubmed: 29479942
Curr Opin Hematol. 2017 Nov;24(6):558-564
pubmed: 28719386
J Clin Lab Anal. 2023 Sep;37(17-18):e24962
pubmed: 37665129
Asian J Transfus Sci. 2014 Jul;8(2):75-7
pubmed: 25161341
Clin Ther. 2020 Feb;42(2):322-337.e2
pubmed: 31882227
Transfusion. 2022 Oct;62(10):2039-2047
pubmed: 35986658
Arch Pathol Lab Med. 2014 May;138(5):684-8
pubmed: 24786127
Blood. 2000 Nov 15;96(10):3369-73
pubmed: 11071629
Hematol Oncol Clin North Am. 2018 Apr;32(2):193-211
pubmed: 29458726
J Pediatr Hematol Oncol. 2011 Aug;33(6):409-14
pubmed: 21792035
Blood Rev. 2019 Sep;37:100588
pubmed: 31324412
Asian J Transfus Sci. 2015 Jan-Jun;9(1):78-81
pubmed: 25722579
Transfus Apher Sci. 2019 Dec;58(6):102678
pubmed: 31753776
Int J Lab Hematol. 2015 Aug;37(4):569-74
pubmed: 25865362
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:76-9
pubmed: 7886613
Arch Med Sci. 2010 Aug 30;6(4):592-8
pubmed: 22371805
Transfusion. 2014 Apr;54(4):972-81; quiz 971
pubmed: 23889533
Expert Rev Hematol. 2021 Oct;14(10):897-909
pubmed: 34493145
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):446-451
pubmed: 27913514
Glob Pediatr Health. 2022 Oct 24;9:2333794X221132679
pubmed: 36310636
Blood Adv. 2021 Feb 9;5(3):737-744
pubmed: 33560383
Lancet. 2022 Jun 18;399(10343):2310-2324
pubmed: 35691301
Pediatr Hematol Oncol. 2011 Sep;28(6):479-85
pubmed: 21854216
Sci Rep. 2020 Dec 3;10(1):21079
pubmed: 33273689
Br J Haematol. 2020 May;189(3):424-427
pubmed: 31961946
Br J Haematol. 2011 Apr;153(1):121-8
pubmed: 21323889
Asian J Transfus Sci. 2014 Jul;8(2):84-8
pubmed: 25161344
Transfusion. 2021 Oct;61(10):3027-3039
pubmed: 34453453
Transfus Apher Sci. 2011 Oct;45(2):199-202
pubmed: 21889408